Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test
Quest Diagnostics has partnered with Octave Bioscience to expand access to the Octave® MS Disease Activity Test in the U.S. Patients can use Quest's 7,000 service centers for specimen collection, enhancing access to advanced diagnostic tools for neurodegenerative diseases. Quest will also offer collection services for future tests by Octave. This collaboration aims to improve care standards for diseases like multiple sclerosis and Parkinson's.
Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. Through this partnership, patients can utilize Quest’s network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson’s disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201400583) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
